Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders.
about
Early intervention in psychosis: concepts, evidence and future directionsAugmentation with antidepressants in schizophrenia treatment: benefit or riskViolence risk assessment in psychiatric patients in China: A systematic reviewOff-label use of sodium valproate for schizophreniaTailoring Cognitive Behavioral Therapy to Subtypes of Voice-Hearing.Feasibility and Effectiveness of a Multi-Element Psychosocial Intervention for First-Episode Psychosis: Results From the Cluster-Randomized Controlled GET UP PIANO Trial in a Catchment Area of 10 Million Inhabitants.Barriers to disseminating brief CBT for voices from a lived experience and clinician perspective.Age differences in mental health literacy.Unmet need for mental health care in schizophrenia: an overview of literature and new data from a first-admission study.A systematic review of the international published literature relating to quality of institutional care for people with longer term mental health problemsPackages of care for schizophrenia in low- and middle-income countries.Factors associated with dental caries among institutionalized residents with schizophrenia in Taiwan: a cross-sectional studyThe Positive and Negative Experiences of Caregiving for Siblings of Young People with First Episode Psychosis.Review: exploring the role of mental health nurse-practitioner in the treatment of early psychosis.Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study.A randomised controlled trial of acceptance and commitment therapy (ACT) for psychosis: study protocol.Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial.Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence.Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR databaseWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Practitioner review: schizophrenia spectrum disorders and the at-risk mental state for psychosis in children and adolescents--evidence-based management approaches.Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.Recognition and optimal management of schizophrenia and related psychoses.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Defining 'elderly' in clinical practice guidelines for pharmacotherapy.Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosisGlutamatergic neurometabolites in clozapine-responsive and -resistant schizophreniaImpact on continuity of care of decentralized versus partly centralized mental health care in Northern Norway.Quantifying clinical relevance in the treatment of schizophrenia.Aripiprazole: the evidence of its therapeutic impact in schizophreniaGender differences in service use in a sample of people with schizophrenia and other psychosesQuo Vadis Clozapine? A Bibliometric Study of 45 Years of Research in International Context.Epidemiology and Treatment Guidelines of Negative Symptoms in Schizo-phrenia in Central and Eastern Europe: A Literature Review.Pharmacological treatment in the early phase of bipolar disorders: what stage are we at?Protocol for a systematic review of telephone delivered psychosocial interventions on relapse prevention, adherence to psychiatric medication and health risk behaviours in adults with a psychotic disorderUse of clozapine for the treatment of schizophrenia: findings of the 2006 research on the china psychotropic prescription studiesA randomized controlled trial of relapse prevention therapy for first-episode psychosis patients: outcome at 30-month follow-upDeclining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?Methamphetamine-associated psychosis: a new health challenge in Iran.Recruitment and treatment practices for help-seeking "prodromal" patients.
P2860
Q24658167-83E9F5F4-AEFF-4F27-8DB6-840337D49C45Q26851841-305745F4-183A-4907-9BCF-BB66EDA115A6Q28085283-E7784090-8CF2-4354-B740-8CDB0B8D8140Q28541404-72DF5561-6B01-4753-A946-288FD161CA5CQ30394450-5D1C7470-800B-4206-A1B3-34E3B04D9F2EQ30660916-A2B14308-181D-4509-B33D-7CC712FD15A6Q30854488-89EA7971-D96C-4916-803A-0A4F49DE6741Q33329311-8A9C2733-EC99-483E-B109-5AEEB903E86BQ33464064-DF936D3D-F1BA-4E4A-B738-E0215CCA8A0AQ33500672-1CBF9872-CE31-44DD-AE6F-CCD409E4E424Q33511434-C5272565-93D3-4F4D-9FDB-169A3CCF204CQ33657397-1AF5A34C-A458-4A8F-A660-F26D6A145323Q33715665-EA6298E3-EA90-476A-A3D8-7E73ABE3593AQ33854754-F13042A0-87EB-47A4-89D7-DC8C07579F14Q33879147-AED6BAB9-6F5D-47AA-B59E-46D2B3A4082FQ33925174-A3E616B7-B454-4E01-8957-D43F6FB9089BQ34075734-85C7BB2F-8A7B-4F91-9CF3-A50033754AE8Q34144373-7BCD0AA4-7829-41EC-8DE6-7F3B143397FBQ34208127-478BFF75-C481-418D-AD3E-FF9F32DA7BABQ34315836-0CFE8778-25AC-45A1-8CBA-E230DD716C91Q34376032-E6EA8F73-F792-4E0F-A283-672D09D2F83BQ34386881-83C6881D-3788-42B5-B66C-60EC4F7DC81EQ34426696-B6713598-60BE-482F-B64F-6DA1F31A6510Q34640811-554F5DE8-0876-4398-BC26-3C89B3F1EE07Q34808432-40F1BE08-9806-437D-8102-7B0ABE4F7C43Q34830869-1F44791A-F054-497B-B736-EC43B897CB27Q35626964-0BEE480B-83C8-4C8D-B837-46C10CF20D3FQ35760975-20BF8A46-4DB9-4045-85F1-3AA7830D258EQ35819467-27F68289-E73E-4333-B99E-3816F75D18E4Q35876413-B603C1D8-39D3-4F71-BF96-57190B756EC2Q36168790-50458F1D-D97D-4A1A-AE52-CC198AF399C6Q36184331-F9AB0B18-3373-4EB8-96BD-2AC3671B0C35Q36232324-1F9F7B0B-466F-4E66-903C-5C5180F41B5AQ36395731-535756BC-F5CD-4E5C-929F-FA8118B51D39Q36406181-7A574263-6613-435E-8D82-51CC4E6490B6Q36600791-D6DCFD93-BAED-47C4-B720-F4FA691DB378Q36621041-7C3740AE-20A8-4206-85A6-CD0401A838D5Q36778605-8DCF4DB5-C9E1-44BD-A24B-C2CB08EAA2FEQ36798032-950944EA-00A0-449C-AD1B-D37D5E2DEADCQ36853314-2452F195-A146-4622-9C14-F57E97ACF575
P2860
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Royal Australian and New Zeala ...... phrenia and related disorders.
@ast
Royal Australian and New Zeala ...... phrenia and related disorders.
@en
Royal Australian and New Zeala ...... phrenia and related disorders.
@nl
type
label
Royal Australian and New Zeala ...... phrenia and related disorders.
@ast
Royal Australian and New Zeala ...... phrenia and related disorders.
@en
Royal Australian and New Zeala ...... phrenia and related disorders.
@nl
prefLabel
Royal Australian and New Zeala ...... phrenia and related disorders.
@ast
Royal Australian and New Zeala ...... phrenia and related disorders.
@en
Royal Australian and New Zeala ...... phrenia and related disorders.
@nl
P2860
P1476
Royal Australian and New Zeala ...... phrenia and related disorders.
@en
P2093
Royal Australian and New Zeala ...... ophrenia and Related Disorders
P2860
P356
10.1111/J.1440-1614.2005.01516.X
P577
2005-01-01T00:00:00Z